The company plans to begin using CleanFuze in spine surgeries within the European Union in June. The company will also submit for clearance from U.S. Food and Drug Administration in the summer of 2014.
DiFusion focuses on reducing surgical site infections in orthopedic surgery through the development of patented antimicrobial orthobiologic polymeric implants.
More Articles on Devices:
Is Biomet Next to Form IPO?
Bioventus Names VP of Global Marketing
Aurora Spine Appoints New VP of Sales
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
